<code id='04D1431EC8'></code><style id='04D1431EC8'></style>
      • <acronym id='04D1431EC8'></acronym>
      <center id='04D1431EC8'><center id='04D1431EC8'><tfoot id='04D1431EC8'></tfoot></center><abbr id='04D1431EC8'><dir id='04D1431EC8'><tfoot id='04D1431EC8'></tfoot><noframes id='04D1431EC8'>
      • <optgroup id='04D1431EC8'><strike id='04D1431EC8'><sup id='04D1431EC8'></sup></strike><code id='04D1431EC8'></code></optgroup>
        5. <b id='04D1431EC8'><label id='04D1431EC8'><select id='04D1431EC8'><dt id='04D1431EC8'><span id='04D1431EC8'></span></dt></select></label></b><u id='04D1431EC8'></u>
          <i id='04D1431EC8'><strike id='04D1431EC8'><tt id='04D1431EC8'><pre id='04D1431EC8'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / fashion      
           
     
           
      
          fashion 
           
      
           
      
           
       2025-10-06 18:09:59 
   
      
           
      
           
                        
          fashion  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：31742
                                  
                                    
          
                                   
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP
          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
          advertisement
          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          UPS workers' union leader explains what's at stake as strike edges closer
                                
                            
          Next article：  
                                      
                                          In age of alternative facts, a scholarly course on calling out crap
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles